Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Low-Grade Serous Ovarian Cancer: early-phase trial registry
3 of 3 indexed Low-Grade Serous Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,224 of 28,963 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,224 of 28,963 conditions by registered trial count
Low-Grade Serous Ovarian Cancer: 3 US clinical trials tracked, 3 recruiting.
Low-Grade Serous Ovarian Cancer is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Verastem, running 1 of these trials.
Open enrollment, early-phase tilt
Low-Grade Serous Ovarian Cancer has 3 registered US clinical trials, 3 of them open to new participants right now, about 100% of the total.
- 3
- recruiting participants now
- 100%
- of trials open to enrollment
- 1
- in Phase 3-4 (later-stage)
- 1
- top sponsor: Verastem
Corpus placement: #5,224 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Low-Grade Serous Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Low-Grade Serous Ovarian Cancer is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
NCT03564340
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem
NCT06072781
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT06394804
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Low-Grade Serous Ovarian Cancer right now
3 recruiting of 3 indexed (100% open).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top sponsor: Verastem (1 trial), 2 others listed. 3 shown below, recruiting first. #5,224 of 28,963 conditions by registered trial count.
Why a small condition index still matters
Thin indexes still surface the registry rows that exist for this label. Counts stay small when ClinicalTrials.gov lists few studies under the condition string, not because this page omits rows. Verify any enrollment decision on ClinicalTrials.gov and with a clinician.
Frequently Asked Questions
How many clinical trials are there for Low-Grade Serous Ovarian Cancer?
PlainTrial tracks 3 US clinical trials for Low-Grade Serous Ovarian Cancer, of which 3 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Low-Grade Serous Ovarian Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.